Selected validation data 驗證

-

  • MetaDx was applied to metastatic cancer to identify the tissue of origin.



  • OncoDx was applied to lung cancer to distinguish malignant tissue from non-tumor.


  • OncoDx was applied to kidney cancer subtyping.


  • Ovarian cancer was discerned from benign tumor or adjacent normal by the gene marker developed at Mao Ying Genetech Inc.


  • OncoDx also functioned with magnetic beads.





留言

發佈留言

此網誌的熱門文章

最新動態 Events

-
圖片
News Patent no. I725248 was issued on Apr. 21, 2021. Mao Ying Participated the Healthcare Expo Taiwan and hosted a booth to introduce the product OncoTeller® to attendees in December of 2019.  Dr. Pei-Ing Hwang was invited to lecture at the symposium emphasizing biotech startups by female founders.  Participating the 2018 BIO International Convention, June 4-7, 2018, Boston, MA Mao Ying Genetech Inc. was elected by the Taipei Municipal Government as one of the five Taipei delegation biotech companies to attend the BIO International Convention of 2018 and hosted the booth #2701 in Boston. (2018-5-28) A company presentation was given by Dr. Pei-Ing Hwang, the founder of Mao Ying Genetech Inc. at the pre-meeting held at Harvard medical school.  An exclusive interview with the broadcaster.  Dr. Hwang, the General Manager of Mao Ying Genetech Inc., received an exclusive interview by the "needs RADIO" global broadcasting network. (2017-11-27) Mao Ying Genetech Inc. recei...
閱讀更多